Product Portfolio

Three non-invasive tests for the three major gynecologic cancers

One DNA methylation platform, three NMPA Class III registered IVDs — cervical, endometrial and ovarian cancer. Every test uses non-invasive sampling and is backed by published multi-center clinical data.

Comparison

Compare the three tests at a glance

Sensitivity and specificity are from the registered clinical trials. Registration numbers are NMPA Class III IVD registrations.

TestCancerGenesSampleSensitivitySpecificityNMPA registration
CISCER®Cervical CancerPAX1 / JAM3Cervical exfoliated cells (non-invasive sampling)89.60%96.50%20233400253
CISENDO®Endometrial CancerCDO1 / CELF4Cervical exfoliated cells (non-invasive sampling)94.51%94.16%20243402610
CISOVA®Ovarian CancerCDO1 / HOXA9Peripheral blood cell-free DNA (non-invasive sampling)93.19%92.78%20253402443

Need the IFU, a distributor quote or a validation study?

Tell us your laboratory setup and intended use. We reply within 1–2 business days with documents, performance data and collaboration options.

  • IFU and registration certificates
  • Clinical performance summary
  • Distributor and study collaboration terms